AlexanderISpiraMD

Oncology • Fairfax, VA

Cancer Genetics/Cancer Risk Assessment, Hematologic Oncology, Sarcoma, Thoracic Cancer

Virginia Cancer Specialists

Join to view full profile

Dr. Spira is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Spira's full profile

Already have an account?

Office
8613 Lee Highway
Fairfax, VA 22031
Phone(703) 280-5390

Fax(703) 280-9596
Is this information wrong?

Education & Training

Johns Hopkins University School of MedicineFellowship, Hematology and Medical Oncology, 2000 - 2003
University of Pennsylvania Health SystemResidency, Internal Medicine, 1997 - 2000
NYU Grossman School of MedicineClass of 1997

Certifications & Licensure

VA State Medical License 2003 - 2024
MD State Medical License 2000 - 2003
PA State Medical License 1998 - 2000
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Top Doctors:Washington DC Area Castle Connolly, 2012
Top Doctors:Washington-Baltimore Castle Connolly, 2012
Top MD Consumers Checkbook

Clinical Trials

Study of the Safety and Efficacy of TH-302 in Combination With Gemcitabine Compared With Gemcitabine Alone in Previously Untreated Patients With Pancreatic Adenocarcinoma Start of enrollment: 2010 Jun 01
Completed
Phase 2
Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer Start of enrollment: 2011 Jan 11
Terminated
Phase 3
A Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Start of enrollment: 2011 Apr 01
Completed
Phase 1, Phase 2
A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
A Study of BBI503 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2012 Feb 01
Completed
Phase 1
LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Start of enrollment: 2013 Jun 28
Active, not recruiting
Phase 3
Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib Start of enrollment: 2013 Aug 01
Completed
Phase 2
BKM120 for Patients With PI3K-activated Tumors Start of enrollment: 2013 Mar 29
Completed
Phase 2
Chemotherapy Plus Cetuximab in Combination With VTX-2337 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Start of enrollment: 2013 Oct 14
Completed
Phase 2
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Etoposide and Platinum Therapy Start of enrollment: 2012 Jan 07
Terminated
Phase 1, Phase 2
MEK162 for Patients With RAS/RAF/MEK Activated Tumors Start of enrollment: 2013 Oct 10
Completed
Phase 2
Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma Start of enrollment: 2013 Dec 13
Active, not recruiting
Phase 3
Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Start of enrollment: 2014 Jan 01
Completed
Phase 1
Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors Start of enrollment: 2014 Mar 01
Completed
Phase 1, Phase 2
Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 16
Terminated
Phase 2
A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Start of enrollment: 2015 Sep 14
Active, not recruiting
Phase 3
Trilaciclib (G1T28) in Patients With Previously Treated Extensive Stage SCLC Receiving Topotecan Chemotherapy Start of enrollment: 2015 Oct 05
Terminated
Phase 1, Phase 2
Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies Start of enrollment: 2018 Feb 22
Recruiting
Phase 1
A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer Start of enrollment: 2019 Apr 01
Active, not recruiting
Phase 1
Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer Start of enrollment: 2020 May 28
Recruiting
Phase 2
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors Start of enrollment: 2020 Feb 24
Recruiting
Phase 1, Phase 2
Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Start of enrollment: 2020 Sep 29
Recruiting
Phase 2
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer Start of enrollment: 2020 Aug 11
Active, not recruiting
Phase 1, Phase 2
Sym021 in Combination With Either Sym022 or Sym023 or Sym023 and Irinotecan in Patients With Recurrent Advanced Selected Solid Tumor Malignancies Start of enrollment: 2020 Oct 12
Recruiting
Phase 1
Join now to see all

Publications & Presentations

PubMed

Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I/II Trial.
Valentina Boni, Mary J Fidler, Hendrik-Tobias Arkenau, Alexander Spira, Funda Meric-Bernstam, Nataliya Uboha, Rachel E Sanborn, Randy F Sweis, Patricia LoRusso, Misako...> ;Clinical cancer research : an official journal of the American Association for Cancer Research. 2022 May 13
1 citations
A phase 1b study evaluating the safety and preliminary efficacy of berzosertib in combination with gemcitabine in patients with advanced non-small cell lung cancer
Ruth Plummer, Emma Dean, Hendrik-Tobias Arkenau, Charles H. Redfern, Alexander I. Spira, Jason M. Melear, Ki Y. Chung, Jordi Ferrer-Playan, Thomas Goddemeier, Giuseppe...> ;Lung Cancer. 2021 Dec 1
10 citations
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline.
Bianca Santomasso, Loretta J. Nastoupil, Sherry Adkins, Christina Lacchetti, Bryan J. Schneider, Milan J. Anadkat, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Cate...> ;Journal of Clinical Oncology. 2021 Nov 1
33 citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update.
Bryan J. Schneider, Jarushka Naidoo, Bianca Santomasso, Christina Lacchetti, Sherry Adkins, Milan J. Anadkat, Michael B. Atkins, Kelly J. Brassil, Jeffrey M. Caterino,...> ;Journal of Clinical Oncology. 2021 Nov 1
3 citations
Changes Over Time in COVID-19 Severity and Mortality in Patients Undergoing Cancer Treatment in the United States: Initial Report From the ASCO Registry.
Kathryn Finch Mileham, Suanna S. Bruinooge, Charu Aggarwal, Alicia L. Patrick, Christiana Davis, Daniel J Mesenhowski, Alexander I. Spira, Eric J. Clayton, David M. Wa...> ;Organic Process Research & Development. 2021 Oct 25
3 citations
The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.
Misako Nagasaka, Vijendra Singh, Yasmine Baca, Ammar Sukari, Chul Kim, Hirva Mamdani, Alexander I. Spira, Dipesh Uprety, Gerold Bepler, Edward S. Kim, Luis E. Raez, Sa...> ;Clinical Lung Cancer. 2021 Oct 18
2 citations
Health-Related Quality of Life, Symptoms, and Tolerability of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Alexander I. Spira, Xiaolei Zhou, Lei Chen, Ari Gnanasakthy, Luqiang Wang, David Ungar, Rafael E. Curiel, Laura Liao, John Radford, Brad S. Kahl> ;Clinical Lymphoma, Myeloma & Leukemia. 2021 Sep 22
12 citations
Brigatinib Versus Crizotinib in ALK Inhibitor-Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial.
D. Ross Camidge, Hye Ryun Kim, Myung-Ju Ahn, James Chih-Hsin Yang, Ji Youn Han, Maximilian Hochmair, Ki Hyeong Lee, Angelo Delmonte, Maria Rosario Garcia Campelo, Dong...> ;Journal of Thoracic Oncology. 2021 Sep 16
6 citations
Characterization of KRAS Mutation Subtypes in Non-small Cell Lung Cancer.
Julia Judd, Nagla Abdel Karim, Hina Khan, Abdul Rafeh Naqash, Yasmine Baca, Joanne Xiu, Ari M. Vanderwalde, Hirva Mamdani, Luis E. Raez, Misako Nagasaka, Sachin Gopalk...> ;Molecular Cancer Therapeutics. 2021 Sep 13
5 citations
Phase II, Randomized Study of Spartalizumab (PDR001), an Anti-PD-1 Antibody, versus Chemotherapy in Patients with Recurrent/Metastatic Nasopharyngeal Cancer.
Caroline Even, Hung-Ming Wang, Shau-Hsuan Li, Roger K-C Ngan, Arunee Dechaphunkul, Li Zhang, Chia Jui Yen, Po Chung Chan, Somvilai Chakrabandhu, Brigette B.Y. Ma, Sueb...> ;Clinical Cancer Research. 2021 Dec 1
2 citations
Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three...
Maen A. Hussein, Marina Maglakelidze, Donald A. Richards, Marielle Sabatini, Todd A Gersten, Keith Lerro, Ivan Sinielnikov, Alexander I. Spira, Yili Pritchett, Joyce M...> ;Cancer management and research. 2021 Aug 9
54 citations
Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase I study
Keunchil Park, Eric B. Haura, Natasha B. Leighl, Paul Mitchell, Catherine A. Shu, Nicolas Girard, Santiago Viteri, Ji-Youn Han, Sang-We Kim, Chee Khoon Lee, Joshua K. ...> ;Journal of Clinical Oncology. 2021 Aug 2
14 citations
Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma.
Adi Diab, Scott S. Tykodi, Gregory A. Daniels, Michele Maio, Brendan D. Curti, Karl D. Lewis, Sekwon Jang, Ewa Kalinka, Igor Puzanov, Alexander I. Spira, Daniel C. Cho...> ;Journal of Clinical Oncology. 2021 Jul 13
4 citations
CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study.
Aung Naing, Fiona C Thistlethwaite, Elisabeth G.E. de Vries, Ferry A.L.M. Eskens, Nataliya Uboha, Patrick A. Ott, Patricia LoRusso, Javier Garcia-Corbacho, Valentina B...> ;Journal for ImmunoTherapy of Cancer. 2021 Jul 1
2 citations
A phase Ib open-label, multicenter study of inhaled DV281, a TLR9 agonist, in combination with nivolumab in patients with advanced or metastatic non-small cell lung ca...
Edward B. Garon, Alexander I. Spira, Melissa Lynne Johnson, Lyudmila Bazhenova, Joseph Leach, Amy L. Cummings, Albert Candia, Robert L. Coffman, Mary J. Janatpour, Rob...> ;Clinical Cancer Research. 2021 Jun 9
126 citations
Sotorasib for Lung Cancers with KRAS p.G12C Mutation.
Ferdinandos Skoulidis, Bob T. Li, Grace K. Dy, Timothy J. Price, Gerald Steven Falchook, Jürgen Wolf, Antoine Italiano, Martin Schuler, Hossein Borghaei, Fabrice Barle...> ;The New England Journal of Medicine. 2021 Jun 4
4 citations
Phase I, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies
Melissa Lynne Johnson, Anthony B. El-Khoueiry, Navid Hafez, Nehal Lakhani, Hirva Mamdani, Jordi Rodon, Rachel E. Sanborn, Javier Garcia-Corbacho, Valentina Boni, Mark ...> ;Clinical Cancer Research. 2021 Jun 3
9 citations
Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study
Mehdi Hamadani, Graham P. Collins, Paolo Caimi, Felipe Samaniego, Alexander I. Spira, Andrew Davies, John Radford, Tobias Menne, Anand B. Karnad, Jasmine Zain, Paul Fi...> ;The Lancet Haematology. 2021 Jun 1
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancer.
Emiliano Calvo, Alexander I. Spira, Maria de Miguel, Shunsuke Kondo, Anas Gazzah, Michael Millward, Hans Prenen, Sylvie Rottey, Lydia Warburton, Tuomo Alanko, Philippe...> ;Cancer treatment and research. 2021 Jan 1
4 citations
A retrospective observational study of the natural history of advanced non-small-cell lung cancer in patients with KRAS p.G12C mutated or wild-type disease.
Alexander I. Spira, Huakang Tu, Shivani Aggarwal, Hil Hsu, Gillis Carrigan, Xuena Wang, Gataree Ngarmchamnanrith, Victoria M. Chia, Jhanelle E. Gray> ;Lung Cancer. 2021 May 25
3 citations
Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies.
Alexander I. Spira, Aaron R. Hansen, Wael A. Harb, Kelly K. Curtis, Erina Koga-Yamakawa, Makoto Origuchi, Zhonggai Li, Bella Ertik, Walid L. Shaib> ;Targeted Oncology. 2021 May 3
2 citations
First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer
Filip Janku, Patricia LoRusso, Aaron S. Mansfield, Rita Nanda, Alexander I. Spira, Tianli Wang, Amal Melhem-Bertrandt, Jennifer Sugg, Howard A. Ball> ;Investigational New Drugs. 2021 Apr 8
2 citations
A phase Ib/II study of pepinemab in combination with avelumab in advanced non–small cell lung cancer
Michael Shafique, Terrence L. Fisher, Elizabeth E. Evans, John E. Leonard, Desa Rae Pastore, Crystal Mallow, Ernest S. Smith, Vikas Mishra, Andreas Schröder, Kevin M. ...> ;Clinical Cancer Research. 2021 Jul 1
4 citations
First-in-human phase I study of ABBV-085, an antibody–drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors
George D. Demetri, Jason J. Luke, Antoine Hollebecque, John D. Powderly, Alexander I. Spira, Vivek Subbiah, Louie Naumovski, Chris Chen, Hua Fang, Dominic W. Lai, Huib...> ;Clinical Cancer Research. 2021 Apr 5
46 citations
Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial.
Gregory J. Riely, Joel W. Neal, D. Ross Camidge, Alexander I. Spira, Zofia Piotrowska, Daniel B. Costa, Anne S. Tsao, Jyoti D. Patel, Shirish M. Gadgeel, Lyudmila Bazh...> ;Cancer Discovery. 2021 Jul 1
Join now to see all

Journal Articles

Differential Regulation of PD-L1 Expression by Immune and Tumor Cells in NSCLC and the Response to Treatment with Atezolizumab (Anti–PD-L1)
Alan Sandler, David S Shames, Hartmut Koeppen, Jamie Chaft, Scott N Gettinger, Alexander Spira, Daniel S Chen, Naiyer A Rizvi, David R Spigel, Proceedings of the National Academy of Sciences
Brigatinib Versus Crizotinib in ALK-Positive Non–Small-Cell Lung Cancer
D Ross Camidge, Scott N Gettinger, Alexander Spira, The New England Journal of Medicine
Cell-Free DNA NGS Prediction of Response and Resistance to a 3rd-Generation EGFR Inhibitor
Alexander I Spira, Helena A Yu, Clinical Lung Cancer

Abstracts/Posters

Safety, Efficacy and Biomarker Analysis of a Phase 1b/2 Study of Onvansertib (ONV), a Polo-like Kinase 1 (PLK1) Inhibitor, in Combination with Low-Dose Cytarabine (LDA...
Alexander I. Spira, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Interim Futility Analysis of a Phase 2 Study of Loncastuximab Tesirine, a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refra...
Alexander I. Spira, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

The Impact of Immunotherapy on a Community Practice. Integrating Immunotherapy Into Clinical Practice: Changes Over the Past Year (Part 2)
2018 ASCO Annual Meeting - Chicago, Illinois - 05/31/2018

Authored Content

WCLC 2021: Study Improvements Mean Nothing Without PatientsFebruary 2021
Cell-Free DNA NGS Prediction of Response and Resistance to a 3rd-Generation EGFR InhibitorAugust 2018

Press Mentions

Advanced Soft Tissue Sarcomas: Dox + Olaratumab vs. Dox + PBOJune 1st, 2019
Insights on Tumor Growth Lead to New TreatmentsFebruary 24th, 2017
Virginia Cancer Specialists Receives Clinical Trials Research Award from Conquer Cancer FoundationJuly 12th, 2016
Join now to see all